ObsEva Annual Report 2021

Rhea-AI Summary

ObsEva SA has released its Annual Report 2021 to Shareholders, detailing the company's developments in women's reproductive health. The report can be accessed via their website. ObsEva is focused on developing therapies for uterine fibroids, endometriosis, and preterm labor. The company utilizes strategic in-licensing and disciplined drug development, and is listed on both NASDAQ under the ticker OBSV and the SIX Swiss Exchange as OBSN.

Positive

• Establishment of a late-stage clinical pipeline focused on women's reproductive health.
• Strategic in-licensing and disciplined drug development enhance potential for successful therapies.

Negative

• None.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

 

Geneva, Switzerland and Boston, MA – March 31, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published its Annual Report 2021 to Shareholders.

The Annual Report 2021 to Shareholders may be found in the financial section of the Company's website, [here]. To access the Annual Report 2021 to Shareholders directly, please click [here].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

For further information, please contact:

CEO Office Contact:
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Katja Bührer
Katja.buhrer@obseva.com
+1 (917) 969-3438

 

###

 

 

Attachment

• Press Release in Pdf

FAQ

What does ObsEva focus on in its Annual Report 2021?

ObsEva's Annual Report 2021 highlights the company's commitment to developing therapies for uterine fibroids, endometriosis, and preterm labor.

Where can I access ObsEva's Annual Report 2021?

The Annual Report 2021 can be accessed in the financial section of ObsEva's website.

What are the stock symbols for ObsEva?

ObsEva is traded on NASDAQ under the symbol OBSV and on the SIX Swiss Exchange as OBSN.

When was ObsEva's Annual Report released?

ObsEva published its Annual Report 2021 to Shareholders on March 31, 2022.